Fondaparinux Reduces All Types of Symptomatic Thromboembolic Complications in Patients with Superficial-Vein Thrombosis in the Legs: Data From the CALISTO Study

被引：3
|
作者：
Leizorovicz, Alain [1 ]
Prandoni, Paolo [2 ]
Decousus, Herve [3 ]
机构：
[1] Fac RTH Laennec, Umr 5558, Lyon, France
[2] Univ Hosp Padua, Padua, Italy
[3] Hop Nord St Etienne, Dept Therapeut & Internal Med, INSERM, CIE3 EA3065, St Etienne, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2310.2310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1001 / 1001
页数：1
相关论文
共 22 条
  • [1] Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs
    Decousus, Herve
    Prandoni, Paolo
    Mismetti, Patrick
    Bauersachs, Rupert M.
    Boda, Zoltan
    Brenner, Benjamin
    Laporte, Silvy
    Matyas, Lajos
    Middeldorp, Saskia
    Sokurenko, German
    Leizorovicz, Alain
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (13): : 1222 - 1232
  • [2] Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study
    Bozzato, Silvia
    Rancan, Elena
    Ageno, Walter
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) : 835 - 837
  • [3] Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study
    Leizorovicz, Alain
    Becker, Francois
    Buchmueller, Andrea
    Quere, Isabelle
    Prandoni, Paolo
    Decousus, Herve
    BLOOD, 2013, 122 (10) : 1724 - 1729
  • [4] Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis
    Blondon, M.
    Righini, M.
    Bounameaux, H.
    Veenstra, D. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 403 - 403
  • [5] Acute isolated superficial-vein thrombosis is associated with substantial comorbidity and history of venous thromboembolic complications
    Sevestre, M-A
    Pouchain, D.
    Gillet, J-L
    Mercier, F.
    Blin, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 122 - 122
  • [6] Fondaparinux 2.5mg for the Treatment of Symptomatic, Isolated Superficial Vein Thrombosis (SVT): Preliminary Data From the Randomized Placebo-Controlled CALISTO Trial (on Behalf of the CALISTO Investigators).
    Decousus, Herve
    Prandoni, Paolo
    Leizorovicz, Alain
    BLOOD, 2009, 114 (22) : 76 - 77
  • [7] Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial
    Beyer-Westendorf, Jan
    Schellong, Sebastian M.
    Gerlach, Horst
    Rabe, Eberhard
    Weitz, Jeffrey I.
    Jersemann, Katja
    Sahin, Kurtulus
    Bauersachs, Rupert
    LANCET HAEMATOLOGY, 2017, 4 (03): : E105 - E113
  • [8] Fondaparinux 2.5 mg for the treatment of symptomatic, isolated superficial thrombophlebitis (ST): preliminary data from the randomized placebo-controlled calisto trial (on behalf of the calisto investigators)
    Decousus, H.
    Leizorovicz, A.
    Prandoni, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 763 - 763
  • [9] Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis The OPTIMEV study
    Galanaud, Jean-Philippe
    Genty, Celine
    Sevestre, Marie-Antoinette
    Brisot, Dominique
    Lausecker, Michel
    Gillet, Jean-Luc
    Rolland, Carole
    Righini, Marc
    Leftheriotis, Georges
    Bosson, Jean-Luc
    Quere, Isabelle
    THROMBOSIS AND HAEMOSTASIS, 2011, 105 (01) : 31 - 39
  • [10] Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study
    Lauren N. Bell
    Richard L. Berg
    John R. Schmelzer
    Hong Liang
    Joseph J. Mazza
    Rajan Kanth
    Christopher L. Bray
    Calixto B. Zaldivar
    Steven H. Yale
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 31 - 37
123